.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Dow
Teva
US Army
Daiichi Sankyo
Baxter
Julphar
UBS
Harvard Business School

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,067,522

« Back to Dashboard

Which drugs does patent 7,067,522 protect, and when does it expire?


Patent 7,067,522 protects COMPLERA, EDURANT, and ODEFSEY, and is included in three NDAs. There has been one Paragraph IV challenge on Complera.

This patent has twenty-five patent family members in twenty-one countries.

Summary for Patent: 7,067,522

Title:2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
Abstract:Pyrimidine derivatives of formula (I) wherein Q.sub.1, Q.sub.2, G and R.sup.1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
Inventor(s): Pease; Elizabeth Janet (Macclesfield, GB), Williams; Emma Jane (Macclesfield, GB), Bradbury; Robert Hugh (Macclesfield, GB), Pearson; Stuart Eric (Macclesfield, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/995,931
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences IncCOMPLERAemtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarateTABLET;ORAL202123-001Aug 10, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
Janssen ProdsEDURANTrilpivirine hydrochlorideTABLET;ORAL202022-001May 20, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
Gilead Sciences IncODEFSEYemtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarateTABLET;ORAL208351-001Mar 1, 2016RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,067,522

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004887Mar 01, 2000

Non-Orange Book Patents for Patent: 7,067,522

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,838,464 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,067,522

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1278735► Subscribe
New Zealand520502► Subscribe
Norway325443► Subscribe
Norway20024126► Subscribe
MexicoPA02007581► Subscribe
South Korea100855258► Subscribe
South Korea20070106806► Subscribe
Japan2003525279► Subscribe
Japan4801335► Subscribe
Japan2005041878► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
UBS
Dow
Federal Trade Commission
Johnson and Johnson
Deloitte
Julphar
Moodys
Colorcon
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot